Long before skincare became a social media trend, Cetaphil was already helping people with sensitive skin. The brand traces its origins back to 1947, when a pharmacist developed the original Cetaphil Cleansing Lotion in Texas, United States. The product was designed to cleanse the skin without causing irritation, making it suitable for people with dry and sensitive skin.
Today, Cetaphil is owned by Galderma, a Swiss dermatology company that was originally established as a joint venture between Nestlé and L’Oréal. Over the decades, the brand has expanded from a single cleanser into a complete skincare portfolio trusted by dermatologists and consumers around the world.
Why Dermatologists Continue to Recommend Cetaphil
Cetaphil has earned its reputation by focusing on clinically tested skincare rather than cosmetic trends. Its products are formulated with ingredients that help maintain the skin’s natural moisture barrier while remaining gentle enough for daily use.
According to Galderma, 9 out of 10 U.S. dermatologists recommend Cetaphil for patients with sensitive skin. Many of its cleansers and moisturizers are fragrance-free, soap-free, hypoallergenic, and suitable for individuals with eczema, rosacea, and acne-prone skin.
Cetaphil’s Best-Selling Products
Several Cetaphil products have remained best sellers for many years because of their dermatologist-backed formulations.
The most popular products include:
- Cetaphil Gentle Skin Cleanser
- Cetaphil Moisturizing Cream
- Cetaphil Daily Facial Cleanser
- Cetaphil Moisturizing Lotion
- Cetaphil PRO Oil Absorbing Moisturizer SPF 30
- Cetaphil Baby Wash & Shampoo
- Cetaphil Healthy Renew Anti-Aging range
These products are widely available through pharmacies, supermarkets, hospitals, dermatology clinics, and online retailers in more than 70 countries.
Want to see the market opportunities, competitor strategies, and regional trends shaping your industry? Download a FREE customized sample report: https://www.towardshealthcare.com/download-sample/5610
The Business Behind Cetaphil’s Growth
Cetaphil has become one of Galderma’s flagship brands and a major contributor to its dermatological skincare business.
Some important business highlights include:
- Cetaphil crossed US$1 billion in annual net sales for the first time in 2023.
- Galderma reported US$4.41 billion in total company net sales during 2024.
- Galderma’s Dermatological Skincare division generated US$1.331 billion in net sales in 2024, increasing 10.7% year over year.
- Galderma operates in more than 90 countries worldwide.
- Dermatological skincare contributes approximately 30% of Galderma’s total business revenue.
Where Is Cetaphil Growing the Fastest?
The United States remains Cetaphil’s largest market, supported by strong dermatologist recommendations and widespread pharmacy availability.
However, Galderma reports that the brand is expanding rapidly across India, China, Brazil, Canada, the United Kingdom, the Philippines, and several other international markets. In 2024, Cetaphil recorded strong market share gains in these countries, while e-commerce became its fastest-growing sales channel.
Amazon sales continued to grow in the United States, while China’s Double-11 shopping festival delivered record online sales for the brand.
What Consumers Really Think
Cetaphil continues to receive strong consumer feedback across major online retailers including Amazon, Walmart, Boots, Target, and CVS.
Many flagship products have accumulated tens of thousands of customer reviews, with average ratings typically ranging from 4.5 to 4.8 stars out of 5.
Consumers most frequently mention:
- Gentle cleansing without irritation
- Excellent hydration for dry and sensitive skin
- Suitable for eczema-prone skin
- Dermatologist recommendation
- Good value for daily skincare
Some consumers prefer the older cleanser formulation introduced before the recent reformulation, while others report that the updated formulas continue to perform well for sensitive skin. Overall, customer satisfaction remains consistently high.
Competition Is Stronger Than Ever
Cetaphil competes in one of the world’s most competitive dermatological skincare markets.
Its biggest global competitors include CeraVe, La Roche-Posay, Aveeno, Eucerin, Vanicream, and Bioderma. While CeraVe has grown rapidly because of its ceramide-based formulations and social media popularity, Cetaphil continues to maintain a leading position through dermatologist recommendations and decades of consumer trust.
According to Galderma, Cetaphil reached US$1 billion in annual sales in 2023 and remains one of the company’s largest skincare brands. The company also reported continued market share gains during 2024 in countries including India, China, Brazil, Canada, and the United Kingdom, demonstrating its ability to compete successfully in both mature and emerging skincare markets.
Government Health Data Supports the Demand
The growing popularity of Cetaphil reflects the increasing number of people living with sensitive skin and chronic skin conditions.
According to the World Health Organization (WHO), skin diseases affect hundreds of millions of people globally each year.
The National Eczema Association estimates that more than 31 million Americans have some form of eczema, while studies referenced by public health agencies indicate that approximately 70% of people worldwide report some degree of skin sensitivity. These figures continue to increase demand for dermatologist-developed skincare products.
From a single pharmacist-created cleanser in 1947 to a billion-dollar global skincare brand, Cetaphil has built its success through scientific research, dermatologist partnerships, and decades of consumer trust.
As awareness of skin health continues to grow worldwide and demand for clinically proven skincare increases, Cetaphil is well positioned to remain one of the world’s leading dermatologist-recommended skincare brands while competing successfully with newer entrants in the premium skincare market.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium